BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes

Monday, 08 February, 2021 | Supplied by: BD AUSTRALIA (Becton Dickinson)

BD (Becton, Dickinson and Company) has announced the CE mark for the BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes with expanded clinical application to help clinicians identify COVID-19 patients at increased relative risk of intubation with mechanical ventilation (IMV) and mortality at hospital admission. By providing deeper understanding of immune responses, clinicians can understand an appropriate course of action for patients while also prioritising the use of hospital resources.

The six-colour direct immunofluorescence reagent can be used with a suitably equipped BD flow cytometer to identify and determine the percentages and absolute counts of T, B and natural killer (NK) cells, as well as the CD4 and CD8 subpopulations of T cells in peripheral blood. It is used in conjunction with the BD FACSLyric and BD FACSCanto II Clinical Flow Cytometers for COVID-19 clinical applications. As shown in clinical studies, some patients with COVID-19 may exhibit a decrease of specific lymphocyte T-cell subsets (CD4+ and/or CD8+ T-cells), and this decrease is associated with increased risk of IMV and mortality. Knowing a patient’s T-cell count can therefore be instrumental in informing the right course of action, and the product may aid in these types of determinations.

Phone: 02 8875 7000
Related Products

HUABIO Cytokeratin 4 Recombinant Rabbit Monoclonal Antibody

Cytokeratin 4 is expressed in the suprabasal layer of the stratified epithelium of the...

Merck ColorWheel flow cytometry antibodies and dyes

The portfolio allows users to independently select antibodies and dyes for assembly in any...

Matreya antibodies directed against ganglioside and globoside glycolipids

Matreya has a range of monoclonal and polyclonal antibodies directed against the carbohydrate...

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd